GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Total Assets

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Total Assets : HK$3,838.9 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Total Assets?

Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was HK$3,838.9 Mil.

During the past 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co's average Total Assets Growth Rate was 10.00% per year.

Total Assets is connected with ROA %. Sichuan Kelun-Biotech Biopharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2023 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. Sichuan Kelun-Biotech Biopharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Sichuan Kelun-Biotech Biopharmaceutical Co Total Assets Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Total Assets Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Total Assets
995.44 1,109.06 3,838.90

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Total Assets Get a 7-Day Free Trial - 1,326.52 1,109.06 2,801.86 3,838.90

Sichuan Kelun-Biotech Biopharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=2547.955+1290.941
=3,838.9

Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=2547.955+1290.941
=3,838.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Total Assets Explanation

Total Assets is connected with ROA %.

Sichuan Kelun-Biotech Biopharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (2801.856+3838.896)/ 2 )
=0/3320.376
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sichuan Kelun-Biotech Biopharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (2801.856+3838.896)/ 2 )
=0/3320.376
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sichuan Kelun-Biotech Biopharmaceutical Co Total Assets Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Total Assets
Comparable Companies
HKSE:01530 HKSE:02162 HKSE:06826 HKSE:09969 HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02105 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Website
http://www.kelun-biotech.com
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines